A New Salvage Regimen for Aggressive Lymphomas Based on Gemcitabine, Rituximab, and Oxaliplatin followed by Lenalidomide (GROC-Rev)
ConclusionGROC-Rev is an effective and well-tolerated salvage regimen consisting of chemotherapy followed by lenalidomide maintenance in patients with R/R NHL. Simultaneous administration of these agents is worth exploring in future study.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
More News: Anemia | Cancer & Oncology | Cellulitis | Chemotherapy | Eloxatin | Leukemia | Lymphoma | Myeloma | Non-Hodgkin's Lymphoma | Pneumonia | Revlimid | Rituxan | Study | Thrombocytopenia | Transplants | Urinary Tract Infections